- Fellowship, clinical pharmacology, Vanderbilt University
- Ph.D., École de Pharmacie, Université Laval, Québec, Canada
- M.Sc., École de Pharmacie, Université Laval, Québec, Canada
- B.Sc., École de Pharmacie, Université Laval, Québec, Canada
Jacques Turgeon, B.Pharm., Ph.D., joined the University of Florida College of Pharmacy as a professor of pharmaceutics and associate dean of the Lake Nona campus in Jan. 2018. As the academic and administrative leader in Lake Nona, he supports the college’s Doctor of Pharmacy program, facilitate research and graduate education, provide guidance for the Center for Quality Medication Management and enhances collaboration amongst UF College of Pharmacy faculty and others in Orlando.
Recognized internationally for his excellence in research and pharmacy education, Turgeon has received more than $70 million in research awards, authored more than 130 peer-reviewed articles and mentored nearly 70 students. His research interests focus on studying factors responsible for the intersubject variability in drug response, and he is renowned for his expertise in the role of pharmacogenetics in cardiovascular drug actions.
Prior to joining UF, Dr. Turgeon has held numerous leadership roles. These include serving as dean of the School of Pharmacy, and vice-rector of research at the University of Montreal, along with director of the University of Montreal Hospital Research Center and then chief executive officer of the University of Montreal Hospital. More recently he served as the chief scientific officer of Tabula Rasa Healthcare and Dean of Tabula Rasa Healthcare University.
Turgeon is a fellow of the Canadian Academy of Health Sciences and the Académie Nationale de Médecine in France. He completed fellowship training in clinical pharmacology at Vanderbilt University and received three degrees, including his Ph.D., from École de Pharmacie, Université Laval in Québec, Canada.
Fellows and Awards
- Fellow, Canadian Academy of Health Sciences
- Fellow, Académie nationale de Médecine, France
- Prix Louis Hébert 2010: Ordre des pharmaciens du Québec
- Dr. Turgeon has received numerous awards for his research activities as well as recognition by the students for his teaching skills. He is a member of numerous societies and has been acting on the committees of several granting agencies for several years.
- Drug metabolism and CYP450s
- Drug-induced Long QT Syndrome
- Clinical decision support systems
- Risk stratification and drug-related adverse events
Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. Eur J Clin Pharmacol. 2016 Aug;72(8):925-31. doi: 10.1007/s00228-016-2065-6. Epub 2016 May 5. PMID:27146814
Turgeon J, Michaud V, Steffen L. The Dangers of Polypharmacy in Elderly Patients. JAMA Intern Med. 2017 Oct 1;177(10):1544. doi: 10.1001/jamainternmed.2017.4790. No abstract available.
Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V. Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics. 2017 Sep 26;9(4). pii: E40. doi: 10.3390/pharmaceutics9040040. PMID:28954402
Turgeon J., Michaud V. Expert Opin Drug Metab Toxicol. 2016 Sep; 12(9):993-5. doi: 10.1517/17425255.2016.1171317. Epub 2016 Apr 11. No abstract available. Erratum in: Expert Opin Drug Metab Toxicol. 2016 Sep; 12 (9):iii.
Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics. 2017 Oct 10;9(4). pii: E42. doi: 10.3390/pharmaceutics9040042.
Hamelin, B.A., Turgeon, J. Hydrophilicity/Lipophilicity : Relevance for the Pharmacology and Clinical Effects of HMG-CoA Reductase Inhibitors. Trends in Pharmacological Sciences (TIPS) 1998; 19:26-37.
Drolet, B., Khalifa, M., Daleau, P., Hamelin, B.A., Turgeon, J. Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval. Circulation, 1998; 97:204-210.
Skrobik, Y., Léger, C., Cossette, M., Michaud, V., Turgeon, J. Predisposing factors to coma and delirium : Fentanyl and midazolam exposure, CYP3A5, ABCB1 amd ABCG2 genetic polymorphisms, and inflammatory factors. Critical Care Med, 2013; doi:10.1097/CCM.0b013e318275d014.
Michaud, V., Bar-Magen, T., Turgeon, J., Desta, Z., Flockhart, D., Wainberg, M. The dual role of pharmacogenetics in HIV treatment : Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev, 2012, 64(3) :803-33.